Effect of L-ornithine-L-aspartate (LOLA) on neurometabolites in hepatic encephalopathy (HE).

被引：0
|
作者：
Mihm, U
Turowski, B
Brinkmann, S
Comes, G
Zeuzem, S
机构：
[1] Univ Frankfurt, D-6000 Frankfurt, Germany
[2] Merz & Co, Frankfurt, Germany
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1483
引用
下载
收藏
页码：543A / 543A
页数：1
相关论文
共 50 条
  • [31] Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial
    Alvares-da-Silva, Mario Reis
    de Araujo, Alexandre
    Vicenzi, Joao Reinhardt
    da Silva, Gabriel Veber
    Oliveira, Fabiana Bazanella
    Schacher, Fernando
    Oliboni, Lucas
    Magnus, Aline
    Kruel, Leticia Pinto
    Prieb, Rita
    Teixeira Fernandes, Luiz Nelson
    HEPATOLOGY RESEARCH, 2014, 44 (09) : 956 - 963
  • [32] Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine
    Garrido, Maria
    Skorucak, Jelena
    Raduazzo, Daniela
    Turco, Matteo
    Spinelli, Giuseppe
    Angeli, Paolo
    Amodio, Piero
    Achermann, Peter
    Montagnese, Sara
    METABOLIC BRAIN DISEASE, 2016, 31 (04) : 965 - 974
  • [33] Parameters determining the agglomeration behavior of anhydrous L-ornithine-L-aspartate (LOLA) crystals prepared by drowning out crystallization
    Kim, Y
    Haam, S
    Kim, WS
    Koo, KK
    KOREAN JOURNAL OF CHEMICAL ENGINEERING, 2003, 20 (06) : 1111 - 1117
  • [34] Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine
    Maria Garrido
    Jelena Skorucak
    Daniela Raduazzo
    Matteo Turco
    Giuseppe Spinelli
    Paolo Angeli
    Piero Amodio
    Peter Achermann
    Sara Montagnese
    Metabolic Brain Disease, 2016, 31 : 965 - 974
  • [35] Parameters determining the agglomeration behavior of anhydrous L-ornithine-L-aspartate (LOLA) crystals prepared by drowning out crystallization
    Yehoon Kim
    Seungjoo Haam
    Woo-Sik Kim
    Kee-Kahb Koo
    Korean Journal of Chemical Engineering, 2003, 20 : 1111 - 1117
  • [36] Pseudopolymorphic crystallization of L-ornithine-L-aspartate by drowning out
    Kim, Y
    Haam, S
    Shul, YG
    Kim, WS
    Jung, JK
    Eun, HC
    Koo, KK
    INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, 2003, 42 (04) : 883 - 889
  • [37] L-Ornithine-L-Aspartate in Experimental Portal-Systemic Encephalopathy: Therapeutic Efficacy and Mechanism of Action
    C. Rose
    A. Michalak
    P. Pannunzio
    G. Therrien
    G. Quack
    G. Kircheis
    R.F. Butterworth
    Metabolic Brain Disease, 1998, 13 : 147 - 157
  • [38] Minimal hepatic encephalopathy: Effect of rifaximin, probiotics and L-ornithine L-aspartate
    Sharma, Kapil
    Pant, Sanjay
    Dwivedi, Manisha
    Misra, S. P.
    Misra, Alok
    Narang, Sushil
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 275 - 276
  • [39] Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy:: results of a placebo-controlled double-blind study
    Stauch, S
    Kircheis, G
    Adler, G
    Beckh, K
    Ditschuneit, H
    Görtelmeyer, R
    Hendricks, R
    Heuser, A
    Karoff, C
    Malfertheiner, P
    Mayer, D
    Rösch, W
    Steffens, J
    JOURNAL OF HEPATOLOGY, 1998, 28 (05) : 856 - 864
  • [40] KALIOPENIC NEPHROSIS - PROTECTIVE ACTION OF L-ORNITHINE-L-ASPARTATE
    RAAB, WP
    CLINICA CHIMICA ACTA, 1972, 39 (01) : 239 - &
12345